10-Q: Viemed Healthcare Reports Strong Q3 Revenue Growth, Strategic Acquisitions Drive Diversification

Viemed Healthcare, Inc. announced robust revenue growth for the third quarter and year-to-date 2025, driven by strategic acquisitions and expansion of its home medical equipment and services.

Summary

• Total revenue for the three months ended September 30, 2025, increased by 24.0% to $71.9 million, up from $58.0 million in the comparable period of 2024.
• Year-to-date revenue for the nine months ended September 30, 2025, grew by 18.7% to $194.1 million, compared to $163.6 million in the prior year.
• Equipment and supply sales revenue saw an 86.0% increase in Q3 2025 to $15.7 million, largely due to the success of the sleep resupply program and the Lehan acquisition's maternal health offerings.
• Ventilator rental revenue increased by 9.8% to $34.9 million in Q3 2025, driven by higher patient volumes and sustained demand.
• Other home medical equipment rentals rose by 23.6% to $15.4 million in Q3 2025, reflecting an expanding patient base for PAP therapy, oxygen therapy, and percussion vest services.
• Net income attributable to Viemed Healthcare, Inc. for Q3 2025 was $3.5 million, a decrease of 9.4% from $3.9 million in Q3 2024, primarily due to non-recurring gains from a ventilator buyback program in the prior year.
• Year-to-date net income attributable to Viemed Healthcare, Inc. increased by 33.8% to $9.3 million for the nine months ended September 30, 2025, compared to $6.9 million in the prior year.
• Adjusted EBITDA for Q3 2025 increased by 15.5% to $16.1 million, up from $14.0 million in Q3 2024.
• The company completed the acquisition of Lehan Drugs, Inc. on July 1, 2025, for approximately $28.7 million, expanding its maternal health services and geographic presence in the Midwest.
• A share repurchase program authorized on June 6, 2025, for up to 1,976,441 common shares, was completed and terminated during Q3 2025, with 1,706,380 shares repurchased for $11.8 million.
• Cash and cash equivalents decreased to $11.1 million at September 30, 2025, from $17.5 million at December 31, 2024, primarily due to the Lehan acquisition and share repurchases.

Sentiment

Score: 8

Explanation: The company demonstrates strong top-line growth, successful strategic acquisitions, and improved operating efficiency. While gross margins saw a slight dip due to revenue mix, and Q3 net income was affected by a prior-year non-recurring gain, the underlying business performance and Adjusted EBITDA growth are robust. The completion of the share repurchase program and proactive engagement with regulatory changes are positive indicators. The need for potential future capital raises for acquisitions is noted but does not detract from current operational strength.

Positives

• Strong overall revenue growth of 24.0% in Q3 2025 and 18.7% year-to-date 2025, indicating robust market demand and successful expansion.
• Significant diversification of revenue streams, with equipment and supply sales increasing by 86.0% in Q3 2025, reducing reliance on ventilator rentals.
• Improved operating leverage, with selling, general and administrative expenses as a percentage of revenue decreasing to 44.4% in Q3 2025 from 46.0% in Q3 2024.
• Adjusted EBITDA increased by 15.5% in Q3 2025 and 17.1% year-to-date, demonstrating healthy operational profitability.
• Successful acquisition of Lehan Drugs, Inc. expands maternal health offerings and geographic footprint, contributing to strategic growth.
• Completion of the 2025 Share Repurchase Program, returning capital to shareholders and indicating confidence in the company's valuation.
• Growth in key operational metrics: Vent Patients increased to 12,372, PAP Therapy Patients to 31,891, and Sleep Resupply Patients to 33,518 by Q3 2025.

Negatives

• Gross profit margin decreased modestly to 57.5% in Q3 2025 from 59.3% in Q3 2024, primarily due to changes in revenue mix associated with product and service diversification.
• Net income attributable to Viemed Healthcare, Inc. decreased by 9.4% in Q3 2025 compared to Q3 2024, largely due to a non-recurring gain from a ventilator buyback program in the prior year.
• Cash and cash equivalents decreased by $6.4 million during the nine months ended September 30, 2025, primarily due to the Lehan acquisition and share repurchases.
• A $0.5 million loss on disposal of property and equipment was recognized in Q3 2025, compared to a $0.5 million gain in Q3 2024, with no material gains expected from the ventilator buyback program in future periods.

Risks

• A reduction or elimination of coverage or reimbursement of products by third-party payors, including Medicare, could adversely affect business and results of operations.
• The new National Coverage Determination (NCD) for noninvasive positive pressure ventilation (NIPPV) in the home for chronic respiratory failure related to COPD, finalized by CMS on June 9, 2025, may significantly affect patient access, reimbursement, and utilization of ventilator therapies.
• Adverse global macroeconomic conditions, including newly imposed tariffs, disruptions to the supply chain, and fluctuations in foreign currency exchange rates, could negatively impact operations, costs, and profitability.
• The expanded scope of recent trade measures and the possibility of further escalation create significant uncertainty around medical equipment pricing and supply availability.
• Global supply chain constraints, such as raw material shortages, longer lead times from suppliers, and increased transportation expenses, may limit responsiveness to patient needs and affect the ability to scale the business effectively.
• Indirect exposure to foreign currency exchange rate fluctuations through international sourcing activities could impact supplier prices and reduce gross margins.
• The federal budget reconciliation legislation (One Big Beautiful Bill Act OBBBA) introduces broad statutory and policy changes that may affect the healthcare industry and operations, with most provisions scheduled for 2027 and 2028.
• Implementation of Pay-As-You-Go (PAYGO) rules could result in future adjustments to Medicare and Medicaid spending, including cost containment measures or payment reductions.
• The company's unsecured claim of $0.9 million against Vyaire Medical, Inc. for undelivered respiratory equipment was deemed uncollectible due to Vyaire's Chapter 11 bankruptcy filing.

Future Outlook

The company anticipates continued organic growth through expansion of existing service areas and new territories, supported by an expanding workforce of Respiratory Therapists. It expects to efficiently scale its business by focusing overhead costs on patient-servicing personnel. The trend of home-based patient care is expected to offer ongoing growth opportunities, positioning the company as a solution to rising healthcare costs. Selling, general and administrative expenses as a percentage of revenue are expected to continue to improve through the end of 2025 due to efficiency initiatives. Research and development costs are expected to remain consistent in 2025 relative to 2024. Stock-based compensation is expected to remain a consistent component of the cost structure. Quarterly net interest expense is expected to reduce for the remainder of 2025 due to anticipated debt repayments. No material gains from the ventilator buyback program are expected in future periods, but certain losses from damaged equipment disposal may continue.

Management Comments

• "Our primary objective is to focus on the organic growth of the business and thereby solidify our position as one of the United States largest providers of in-home therapy for patients suffering from respiratory diseases."
• "We expect to grow through expansion of existing service areas as well as in new territories through a cost efficient launch that reduces location expenses."
• "We anticipate expanding our workforce of RTs to support our growth and ensure our high service model is maintained in the home."
• "By focusing overhead costs on personnel that service the patient rather than physical location costs, we anticipate that we will efficiently scale our business in territories that are currently not being effectively serviced."
• "The continued trend of servicing patients in the home rather than in hospitals is aligned with our business objective and we anticipate that this trend will continue to offer growth opportunities for us."
• "We expect to continue to be a solution to the rising health costs in the United States by offering more cost effective, home based solutions while increasing the quality of life for patients fighting serious respiratory diseases."
• "We expect continued growth and scale to support improved cost efficiencies over time. However, the evolving revenue mix may partially offset these benefits. As a result, gross margins may fluctuate in future periods depending on the composition of revenue sources and the degree to which economies of scale are realized."
• "We expect that selling, general and administrative expenses as a percentage of revenue will continue to improve through the end of 2025 supported by ongoing efficiency initiatives and disciplined cost management."
• "As we continue to invest in research and development related projects to support our technology initiatives, we expect that the associated costs will remain consistent in 2025 relative to 2024."
• "As we expand our workforce and align employee incentives with long-term shareholder value, we expect stock-based compensation to remain a consistent component of our cost structure throughout the remainder of 2025."
• "With anticipated debt repayments, we expect a reduction in quarterly net interest expense for the remainder of 2025."

Industry Context

The home medical equipment market, particularly complex respiratory and Obstructive Sleep Apnea (OSA) device segments, is experiencing sustained expansion with projected CAGRs of approximately 6% for respiratory devices and 8% for OSA devices. The aging population and rising incidence of chronic diseases are key drivers, alongside a notable shift towards home-based treatment. U.S. home healthcare spending is projected to reach $250 billion by 2031, with a CAGR of approximately 7%. Market consolidation favors larger, financially stable players due to capital investment and scale requirements. The industry is transitioning to value-based healthcare, with HME providers leveraging data analytics to demonstrate cost-effectiveness. Regulatory developments, such as CMS's new NCD for NIPPV and proposed reforms to the Medicare Competitive Bidding Program, are shaping the landscape, potentially benefiting larger operators with greater scale and compliance capabilities. The federal budget reconciliation legislation (OBBBA) also introduces broad policy changes affecting healthcare, mostly effective 2027-2028.

Comparison to Industry Standards

• The company's revenue growth of 24.0% in Q3 2025 and 18.7% YTD 2025 significantly outpaces the projected industry Compound Annual Growth Rates (CAGR) of approximately 6% for respiratory devices and 8% for OSA devices, indicating strong market penetration and expansion.
• The company's focus on home-based treatment aligns with the broader industry trend of shifting patients from acute care settings to home care, which is expected to drive U.S. home healthcare spending to $250 billion by 2031 with a CAGR of approximately 7%.
• As a larger, financially stable player, the company is well-positioned to benefit from market consolidation trends, where smaller regional players are declining due to capital and scale requirements.
• The company's active participation in CMS's national coverage analysis for NIPPV and engagement with regulatory bodies demonstrates its proactive approach to navigating policy changes, which is crucial for larger providers in a highly regulated industry.

Corporate Governance

Legal Proceedings

• The company's lawsuit against Vyaire Medical, Inc. for breach of contract resulted in a Partial Summary Judgment in favor of Viemed on September 5, 2023.
• Vyaire filed for Chapter 11 bankruptcy on June 9, 2024, leading to the determination that collection of Viemed's unsecured claim of $0.9 million (related to undelivered respiratory equipment) is not probable and was impaired in 2024.

Stakeholder Impact

• Shareholders: Benefit from strong revenue and Adjusted EBITDA growth, improved operating leverage, and the completion of a share repurchase program. Potential for future dilution if equity financing is pursued for acquisitions.
• Employees: Continued investment in employee retention and long-term incentive programs through stock-based compensation, and expansion of the workforce, particularly Respiratory Therapists.
• Customers (Patients): Benefit from expanded service offerings, including maternal health services from the Lehan acquisition, and the company's focus on in-home therapy and improved patient outcomes.
• Suppliers: Subject to global macroeconomic conditions, including tariffs and supply chain disruptions, which could affect pricing and availability of medical equipment.
• Creditors: The company was in compliance with all covenants under its 2022 Senior Credit Facilities as of September 30, 2025, and made a $5.0 million repayment on its revolving credit facility post-period end, indicating sound debt management.

Next Steps

• Continue organic growth through expansion of existing service areas and new territories.
• Expand the workforce of licensed Respiratory Therapists to support growth and maintain high service standards.
• Monitor and adapt to regulatory developments, including the implementation of the new CMS NCD for NIPPV and provisions of the OBBBA.
• Manage cost pressures through inflation-linked reimbursement contracts, negotiation, leveraging purchasing power, and technology adoption.
• Evaluate the impact of recently issued accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-06) on consolidated financial statements and disclosures.
• Anticipate debt repayments to reduce quarterly net interest expense for the remainder of 2025.
• Potentially seek additional funds through equity, equity-linked, or debt financings to support contractual obligations and investing activities beyond the next 12 months, especially for acquisitions.

Key Dates

Recommendation

Viemed Healthcare demonstrates strong fundamental performance with significant revenue growth, particularly in diversifying segments like equipment sales and other HME. The company is effectively leveraging its operations, as evidenced by improved SG&A as a percentage of revenue and robust Adjusted EBITDA growth. While Q3 net income was lower year-over-year, this was due to a non-recurring gain in the prior period, and year-to-date net income shows substantial improvement. Strategic acquisitions like Lehan Drugs, Inc. are expanding the company's market reach and service offerings. The completion of a share repurchase program signals management's confidence and commitment to shareholder value. Despite potential regulatory shifts and macroeconomic risks, Viemed's proactive stance and strong operational execution position it well for continued growth in the expanding home healthcare market. This makes it an attractive 'buy' for investors seeking growth in the healthcare sector.

Keywords

Home Medical Equipment, Respiratory Care, Ventilator Rentals, Sleep Apnea Treatment, Maternal Health, Healthcare Staffing, SEC Filing, 10-Q, Viemed Healthcare, VMD, Acquisition, Share Repurchase, Medicare, CMS, DMEPOS